ONCY (Oncolytics Biotech) Research & Development: $14.97 Mil (TTM As of Mar. 2026)


ONCY Oncolytics Biotech Inc ONCY
31 GF Score
Price $0.94
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech Research & Development?

Oncolytics Biotech ONCY +2.62% 31 Research & Development is $14.97 Mil as of Mar. 2026. GuruFocus rates ONCY with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Oncolytics Biotech's Research & Development for the three months ended in Mar. 2026 was $4.55 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $14.97 Mil.

Oncolytics Biotech  (NAS:ONCY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oncolytics Biotech Research & Development Related Terms

Oncolytics Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech Research & Development Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.13 11.37 13.35 15.44 13.31

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.80 2.05 5.40 2.96 4.55
ONCY
31GF Score
Oncolytics Biotech Inc ONCY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $14.97 Mil mean?
Oncolytics Biotech (ONCY) has a Research & Development of $14.97 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Oncolytics Biotech and its competitors.
Is Oncolytics Biotech's Research & Development too high?
Oncolytics Biotech's current Research & Development is $14.97 Mil. Overall, Oncolytics Biotech has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's Research & Development compare to ALPS and KLRS?
Oncolytics Biotech's Research & Development of $14.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oncolytics Biotech and its competitors. Oncolytics Biotech's current Research & Development is $14.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current Research & Development of $14.97 Mil. The current Research & Development is $14.97 Mil. Oncolytics Biotech's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current Research & Development is $14.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
31GF Score

Get the complete analysis for ONCY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.94
Price